Add to ORKGAbbreviations: (ALT) alanine aminotransferase, (BMI) body mass index, (GLP 1) glucagon-like peptide-1, (HbA1c) glycated hemoglobin, (HDL-C) high-density lipoprotein cholesterol, (LAR) long-acting release, (MET) metformin, (NAFLD) nonalcoholic fatty liver disease, (SFU) sulfonylureas, (TZD) thiazolidinedion
Exenatide is the first in a novel class of drugs that mimics naturally occurring glucagon-like pepti...
Background: The aim of this study was to evaluate the effect of exenatide on fat deposition and a me...
Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with metabolic syndrome and...
Background/aim: The aim of this study was to evaluate the effects of a 6-month treatment regimen wit...
BackgroundMost type 2 diabetes mellitus patients are obese and have obesity related vascular complic...
Elaine Chiquette,1 Peter P Toth,2 Gilbert Ramirez,3 Michael Cobble,4 Robert Chilton51Amylin Pharmace...
It is known that at DM2 is raised considerably risk of development of myocardial infarction (MI) and...
Peggy Soule Odegard1, Anthony DeSantis21School of Pharmacy, 2Division of Metabolism, Endocrinology a...
Aim To conduct a prospective randomized trial to investigate the effect of glucagon-like peptide-1 (...
International audienceTo conduct a prospective randomized trial to investigate the effect of glucago...
Catherine A Schnabel, Matthew Wintle, Orville KoltermanAmylin Pharmaceuticals, Inc, 9360 Towne Centr...
The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: The...
OBJECTIVE: The risk of cardiovascular morbidity and mortality is significantly increased in patient...
Background Dyslipidemia and type 2 diabetes are two of the most significant risk factors f...
Type 2 diabetes mellitus (T2DM) is a well-recognized risk factor for the development of cardiovascul...
Exenatide is the first in a novel class of drugs that mimics naturally occurring glucagon-like pepti...
Background: The aim of this study was to evaluate the effect of exenatide on fat deposition and a me...
Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with metabolic syndrome and...
Background/aim: The aim of this study was to evaluate the effects of a 6-month treatment regimen wit...
BackgroundMost type 2 diabetes mellitus patients are obese and have obesity related vascular complic...
Elaine Chiquette,1 Peter P Toth,2 Gilbert Ramirez,3 Michael Cobble,4 Robert Chilton51Amylin Pharmace...
It is known that at DM2 is raised considerably risk of development of myocardial infarction (MI) and...
Peggy Soule Odegard1, Anthony DeSantis21School of Pharmacy, 2Division of Metabolism, Endocrinology a...
Aim To conduct a prospective randomized trial to investigate the effect of glucagon-like peptide-1 (...
International audienceTo conduct a prospective randomized trial to investigate the effect of glucago...
Catherine A Schnabel, Matthew Wintle, Orville KoltermanAmylin Pharmaceuticals, Inc, 9360 Towne Centr...
The Author(s) 2014. This article is published with open access at Springerlink.com Introduction: The...
OBJECTIVE: The risk of cardiovascular morbidity and mortality is significantly increased in patient...
Background Dyslipidemia and type 2 diabetes are two of the most significant risk factors f...
Type 2 diabetes mellitus (T2DM) is a well-recognized risk factor for the development of cardiovascul...
Exenatide is the first in a novel class of drugs that mimics naturally occurring glucagon-like pepti...
Background: The aim of this study was to evaluate the effect of exenatide on fat deposition and a me...
Non-alcoholic fatty liver disease (NAFLD) is a common disease associated with metabolic syndrome and...